07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Oral one-alpha D2 data

BCII published results of a Phase II trial in Kidney International. The compound, which converts into the natural form of vitamin D to inhibit the secretion of parathyroid hormone (PTH), was able to reduce PTH...
07:00 , Jul 10, 2006 |  BC Week In Review  |  Company News

Savient management update

Savient Pharmaceuticals Inc. (SVNT), East Brunswick, N.J.   Business: Metabolic   Hired: Brian Hayden as SVP, CFO and treasurer, formerly VP of finance and CFO at Bone Care International Inc.  ...
01:20 , Jul 7, 2006 |  BC Extra  |  Company News

Savient names Hayden CFO

Metabolic company SVNT hired Brian Hayden as SVP and CFO. He was previously VP of finance and CFO at Bone Care International, which was acquired by Genzyme (GENZ) last year. SVNT gained $0.34 to $5.67...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

Allos management update

Allos Therapeutics Inc. (ALTH), Westminster, Colo.   Business: Cancer   Hired: James Caruso as EVP and chief commercial officer, formerly SVP of sales and marketing at Bone Care International Inc.  ...
08:00 , Mar 13, 2006 |  BC Week In Review  |  Company News

Allos management update

Allos Therapeutics Inc. (ALTH), Westminster, Colo.   Business: Cancer   Hired: Paul Berns as president, CEO and a director, formerly president, CEO and director at Bone Care International Inc.   Resigned: Michael Hart as president,...
02:37 , Mar 11, 2006 |  BC Extra  |  Company News

Allos names Berns CEO

Cancer company ALTH hired Paul Berns as president, CEO and a director. Previously, Berns was president, CEO and director at Bone Care International, which was acquired by Genzyme (GENZ) last year. He replaces Michael Hart,...
08:00 , Dec 5, 2005 |  BC Week In Review  |  Company News

XenoPort board of directors update

XenoPort Inc. (XNPT), Santa Clara, Calif.   Business: Drug delivery   Appointed: Paul Berns, former president and CEO of Genzyme Corp.'s Bone Care International Inc. subsidiary  ...
07:00 , Jul 18, 2005 |  BC Week In Review  |  Company News

Bone Care, Genzyme deal

GENZ completed its previously announced acquisition of BCII for about $719 million in cash (see BioCentury, May 9). Bone Care International Inc. (BCII), Middleton, Wis.   Genzyme Corp. (GENZ), Cambridge, Mass.   Business: Musculoskeletal, Renal,...
01:28 , Jul 15, 2005 |  BC Extra  |  Top Story

Genzyme beats Street

GENZ reported second quarter 2005 non-GAAP EPS of $0.57, beating the Street estimate by $0.04 and up 30% from $0.44 in the second quarter of 2004. Second quarter revenues increased 22% to $668.1 million from...
07:00 , May 9, 2005 |  BC Week In Review  |  Company News

Bone Care, Genzyme deal

GENZ will acquire BCII for about $33 per share, or $719 million, in cash. The deal price is a 38% premium to BCII's close of $23.83 on Tuesday, before the deal was announced. Net of...